ReviewCurrent opinion in HIV and AIDS2015
The current status of the use of oral medication to prevent HIV transmission.
Review in Current opinion in HIV and AIDS, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support.AIDS and behavior · 2016Trial
- Exploring Effects of Race and Differential Item Functioning on PrEP Stigma Experiences: Implications for Latent Stigma Measurement in Racially and Sexually Diverse Populations.AIDS and behavior · 2024Article
- Article
- Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe.Frontiers in medicine · 2021Review
- Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California.AIDS education and prevention : official publication of the International Society for AIDS Education · 2020Article
- The Ashodaya PrEP project: Lessons and implications for scaling up PrEP from a community-led demonstration project among female sex workers in Mysore, India.Global public health · 2020Article
- Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivirine/Emtricitabine in Digital Pills.AIDS research and human retroviruses · 2019Article
- Context-Appropriate Interventions to Prevent Syphilis: A Narrative Review.Sexually transmitted diseases · 2018Review
- HIV and sexually transmitted infections: responding to the "newest normal".Journal of the International AIDS Society · 2018Article
- Prevention paradox: Medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need.Journal of the International AIDS Society · 2018Article
- Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C.Current HIV/AIDS reports · 2018Review
- Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women.PloS one · 2018Article
- Pre-exposure Prophylaxis: The Delivery Challenge.Frontiers in public health · 2018Review
- Evolving treatment implementation among HIV-infected pregnant women and their partners: results from a national surveillance study in Italy, 2001-2015.Journal of global health · 2017Article
- "Support Your Client at the Space That They're in": HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation.AIDS patient care and STDs · 2017Article
- Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action.Journal of acquired immune deficiency syndromes (1999) · 2016Article
- The Potential of Pre-Exposure Prophylaxis for Women in Violent Relationships.AIDS patient care and STDs · 2016Review
- A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.The Journal of antimicrobial chemotherapy · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewThis review was designed to evaluate the progress in studies of the use of oral and topical antiretroviral (ARV) medication for primary HIV prevention. RECENT
findingsNonhuman primate data have suggested that the administration of ARV medication before or after retroviral exposure can protect against the establishment of chronic infection. Over the past two decades, observational studies have demonstrated the safety of ARV agents for postexposure prophylaxis and more recent efficacy studies have demonstrated that tenofovir with or without emtricitabine can protect against HIV when used as preexposure prophylaxis (PrEP). Efficacy studies have been conducted in diverse populations, including men and transgender women who have sex with men, young African heterosexuals, and injection drug users. Three studies in African women evaluating oral and topical tenofovir-based regimens did not demonstrate efficacy, in large part because of suboptimal medication adherence. Further research is underway to determine the optimal ways to provide chemoprophylaxis, the optimal medications, and dosing regimens. SUMMARY: PrEP can be effective in decreasing HIV transmission to at-risk uninfected persons, but further research is needed to determine the optimal modes of delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.